At a Mount Druitt medical practice where four in five patients are overweight and obese, a woman struggles to rise from her chair, her muscles having wasted away.
Dr Kean-Seng Lim’s western Sydney waiting room is a stark reminder of the great potential, and potential risks of GLP-1s such as Wegovy and Ozempic (semaglutide).
“They are powerful tools if used well, but they can be a double-edged sword,” Lim, a GP for more than 30 years and former Australian Medical Association NSW president.
A surge in demand for GLP-1 medications is expected to accelerate, with the first two oral GLP-1s – Novo Nordisk’s Wegovy pill and Lilly’s Foundayo – arriving at pharmacies for patients with private prescriptions.
GLP-1s, approved for chronic weight management when combined with diet and exercise, can be life-changing, triggering significant weight loss and lowering the risk of obesity-related health complications. Semaglutides have also been shown to lower the risk of heart attack, stroke and cardiovascular death.
But clinicians and researchers have cautioned against mistaking GLP-1s for a silver bullet, warning muscle wastage and a great weight rebound was on the horizon for those who do.
“But worryingly, the focus for these agents has been on weight, rather than health,” Lim said.
Kean-Seng recalled one of his patients, a woman aged over 60, who was having great difficulty getting out of her chair.
She had been prescribed GLP-1s via another provider with no follow-up or diet and exercise advice, reduced her food intake and, critically, wasn’t eating enough protein, Kean-Seng said.
“On further assessment using a body composition analysis, we found that she had lost 10 kilograms of muscle mass and gained one kilogram of fat mass, and she was now at quite a significant risk of falls,” Lim said.
“As with any powerful drug, we have got to use it properly. We need to be monitoring patients properly, ideally through a multidisciplinary team, because there are very real risks.”
Among them was malnutrition, muscle wastage and developing unhealthy eating habits “such that they either rapidly regain weight when they stop [using GLP-1s] or they end up worse off with lower muscle mass, increased risk of falls and increased risk of other harms.”
By 2036, between 17 and 30 per cent of the Australian population – up to 7 million people – could be using GLP-1s, according to EY-Parthenon modelling published in July.
Clinical trials and real-world data consistently shows that stopping GLP-1 use leads to a rapid rebound in weight and a reversal of improvements in cardio-metabolic risk factors.
“Ultimately, we do find that very few patients actually stay on these medications on an ongoing basis even though all the studies have shown that once the medication stops, there is usually great weight gain,” Lim said.
He said responsible GLP-1 use involves planning for this eventuality by adopting healthy diet and exercise habits so that they don’t regain the weight they lost, or keep the regained weight to a minimum.
“On the bright side, when used well and with good nutritional support, preferably with an experienced dietitian, and with good exercise support, we can get very good results,” he said.
“In the best-case scenario, we have patients who either maintain or even improve their muscle mass while reducing fat mass, which we know improves their metabolic rate and reduced their rate of weight regain.”
Start the day with a summary of the day’s most important and interesting stories, analysis and insights. Sign up for our Morning Edition newsletter.
From our partners
Disclaimer : This story is auto aggregated by a computer programme and has not been created or edited by DOWNTHENEWS. Publisher: www.smh.com.au





